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Abstract 
Benznidazole is the front-line drug used against Trypanosoma cruzi, the causative 
agent of Chagas disease. This pro-drug is activated within the parasite by a 
mitochondrial type I nitroreductase. Loss or disruption of a single copy of the gene 
encoding this flavoprotein is sufficient to cause resistance to benznidazole and other 
nitroheterocycle drugs, including nifurtimox. Here, we demonstrate that distinct cross-
resistant clones can arise independently within a single population. Following 
selection of benznidazole-resistant parasites, we found that all clones examined had 
lost one of the chromosomes containing the TcNTR gene. Sequence analysis of the 
remaining TcNTR allele revealed the presence of three distinct mutant genes in 
different resistant clones, each arising from missense mutations. Expression studies 
showed that, unlike the enzyme from the parental sensitive strain, those from the 
resistants were unable to reduce benznidazole. This correlated with loss of FMN-
binding. The drug-resistant phenotype could be reversed by transfection with an 
active copy of the TcNTR gene. These results provide further evidence that TcNTR is 
a central player in the development of resistance to the therapeutic drugs used against 
Chagas disease. They also demonstrate that T. cruzi has a propensity to readily 
undergo genetic changes that can lead to drug-resistance under selective pressure, a 
finding that has implications for future therapeutic strategies.  
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\body 
Introduction 
Chagas disease is caused by Trypanosoma cruzi, a flagellated protozoan parasite 
transmitted by blood-sucking triatomine bugs. In Latin America, 10 million people 
are infected, with >15,000 deaths annually (1). Due to migration, the disease is also 
undergoing globalisation. In the USA, there are an estimated 300,000 infected 
individuals (2). Chagas disease has three phases; acute, indeterminate and chronic. 
The acute stage is usually asymptomatic, although it can present as a febrile-like 
illness in children and young adults, with a fatality rate up to 5%. Most symptoms 
resolve within 4-6 weeks and patients enter the indeterminate stage. Usually, active 
disease does not proceed further. However, ~30% of individuals progress to the 
chronic phase, a process that can occur many years after the initial infection. This can 
result in serious cardiac and digestive tract pathologies, where prognosis is poor.  
 
There is no immediate prospect of a Chagas disease vaccine and infection is life-long. 
Chemotherapy is therefore of major importance. For many years, benznidazole and 
nifurtimox have been the only drugs available (3). However, their use is characterised 
by toxicity and their efficacy against chronic stage disease is unreliable. In addition, 
cases refractory to treatment are commonly reported (4) and drug-resistant parasites 
can be selected in the laboratory (5, 6). Benznidazole and nifurtimox are 
nitroheterocyclic compounds which contain a nitro group linked, respectively, to an 
imidazole and furan ring (3). They are pro-drugs and require nitroreductase (NTR)-
catalysed activation within the parasite to have trypanocidal effects. Two classes of 
NTR have been identified in trypanosomes (7). Type II NTRs are O2-sensitive flavin-
containing enzymes which are capable of 1-electron reduction of nitro-drugs to 
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generate an unstable nitro-radical. In the presence of O2, this leads to the production 
of superoxide anions and regeneration of the parent nitro-compound, a process known 
as redox cycling (8, 9). Although activation of benznidazole and nifurtimox by T. 
cruzi has been associated with the formation of reactive oxygen species (ROS), and 
candidate reductases have been implicated, there is no direct experimental evidence of 
a significant correlation between drug-induced ROS and trypanocidal activity (10-15).  
 
Type I NTRs are O2-insensitive FMN-dependent enzymes that can mediate the 2-
electron reduction of nitro-drugs through a nitroso, to hydroxylamine derivatives. 
These can react further to generate nitrenium cations and other highly electrophilic 
intermediates which may promote damage to DNA and other macromolecules (16, 
17). Two enzymes with type I activity have been identified in T. cruzi. The first is 
prostaglandin F2α synthase (18), although this is only capable of mediating 2-electron 
reduction under anaerobic conditions. The second, for which there is now strong 
evidence of a central role in activating both benznidazole and nifurtimox, is a NADH-
dependent mitochondrial type I NTR (5). In the case of nifurtimox, the active 
metabolite is an unsaturated open chain nitrile (19).  
 
TcNTR can reduce a range of nitroheterocycles and deletion of the corresponding 
genes from T. cruzi and T. brucei results in loss of sensitivity (5). The first evidence 
that loss of TcNTR activity might be an important mechanism for causing drug-
resistance came from analysis of laboratory-generated nifurtimox-resistant T. cruzi 
(5). These were found to lack one of the chromosomes containing the TcNTR gene 
and to exhibit cross-resistance to benznidazole. Consistent with this, a genome-wide 
RNAi screen of T. brucei for genes associated with nifurtimox and benznidazole 
5 
 
resistance by loss-of-function mechanisms identified TbNTR as the major candidate 
(20).   
 
To investigate the capacity of T. cruzi to develop resistance against benznidazole, we 
generated resistant clones following in vitro selection. Here, we show that distinct 
drug-resistant clones can arise independently, and that in each case, resistance under 
selective pressure is associated with loss of TcNTR activity. 
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Results  
Benznidazole-resistant T. cruzi lack one of the chromosome bands containing the 
TcNTR gene. To select for benznidazole-resistance, T. cruzi GAL61 (Table 1) were 
submitted to continuously increasing drug pressure until we had established a 
population (61R) that grew at a comparable rate in the presence or absence of 50 µM 
benznidazole (Materials and Methods). This population displayed ~10-fold resistance. 
Six clonal lines derived from this population exhibited between 3- and 7-fold 
resistance, when examined independently (Fig. 1A). In the absence of drug, the clones 
grew slightly slower in culture that the parental cells (doubling times from 28–42 
hours, compared to 26 hours), but otherwise displayed no obvious morphological 
changes. Previously, when we generated nifurtimox-resistant T. cruzi, we found that 
they were also resistant to other nitroheterocyclic drugs, including benznidazole (5). 
A similar cross-resistance phenomenon was observed here, with 2-fold greater 
resistance to nifurtimox and 4-fold to nitrofurazone (Fig. 1B).  
 
Nifurtimox-resistance in both T. cruzi and T. brucei has been associated with down-
regulation or loss of a type I NTR gene (5, 20). We therefore examined the 
benznidazole-sensitive and resistant cells for changes in copy number at this locus. In 
the sensitive parental cells (61S), TcNTR is a single copy gene located on 
chromosome homologues of 1.1 and 0.85 Mb. With the resistant parasites however, 
the 0.85 Mb band was missing in clonal and polyclonal populations (Fig. 1C, lanes 2 
and 3). There were no other apparent changes to the chromosome profile. To 
determine if drug-resistance was associated with loss of TcNTR, rather than another 
gene located elsewhere on the missing chromosome, we re-introduced an active copy 
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of TcNTR into 61R clone 2 (21, Fig. 1D). When the transformed cells were assessed, 
we found that benznidazole-sensitivity had been restored. 
 
The remaining TcNTR allele in each benznidazole-resistant clone encodes an 
inactive protein. We next investigated if the remaining chromosomal copy of TcNTR 
in the benznidazole-resistant 61R parasites had altered. Genes from the 6 resistant 
clones were amplified and sequenced. Missense mutation(s) were identified in each 
case. In clones 1, 2, 4 and 5, there was C/T transition at position 374, compared with 
the TcNTR gene amplified from sensitive clones. In the protein, this would result in 
replacement of the evolutionarily conserved Pro-125 with leucine (Fig. 2). With clone 
6, in addition to the mutation at position 374, we also identified a missense mutation 
at nucleotide 460 (C/G), giving rise to the conversion of Pro-154 to alanine. For clone 
3, there was a single missense mutation resulting in C/G transversion at nucleotide 
477, leading to the replacement of Phe-159 with leucine. No other mutations were 
observed in the TcNTR genes isolated from the resistant clones. In the O2-insensitive 
E. coli nitroreductase nfsB, most mutations associated with nitrofuran resistance are 
located in the corresponding region to those in TcNTR (22, 23; Fig. 2).  
 
To determine if the TcNTR mutations had perturbed activity, we amplified a fragment 
encoding the catalytic region of the enzyme using DNA from 61S and 61R clones 3, 4 
and 6. TcNTR is mitochondrial and previous attempts to express active full length 
enzyme had been unsuccessful. Activity was only detectable when the amino terminal 
domain was excluded from the recombinant protein (Fig. 2; 5). After sequence 
confirmation, the expressed histidine-tagged proteins were purified on nickel columns 
(Materials and Methods; Fig. 3A). Fractions containing recombinant protein derived 
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from the 61S TcNTR gene were yellow, as expected of a flavoprotein. Those 
containing enzyme derived from the resistant clones were colourless. 
 
The capacity of the recombinant enzymes to reduce benznidazole and nifurtimox was 
established from double reciprocal plots of 1/TcNTR activity against 1/[drug], at a 
fixed NADH concentration (100 μM) (Materials and Methods, Fig. 3B, C). For the 
enzyme derived from the sensitive clone, we established apparent Km values of 26 μM 
for benznidazole and 18 μM for nifurtimox. Further analysis gave apparent Vmax 
values of 1933 and 389 nmol NADH oxidised min-1 mg-1 for benznidazole and 
nifutimox, respectively. When each of the mutant TcNTRs were analysed, no activity 
could be detected, even when 10 times as much recombinant protein was used. We 
then investigated the mutant proteins for flavin binding (Fig. 3D) using fluorescent 
detection under neutral and acidic conditions (Materials and Methods). At neutral pH 
and using an excitation wavelength of 450 nm, the FMN standard and 61S TcNTR-
derived co-factor both gave a fluorescence profile that peaked at 535 nm, a signal 
which was quenched under acidic conditions. By contrast with FAD, the 535 nm peak 
occurs at pH2 and is quenched at pH7. No flavin fluorescence was detected with 
mutant TcNTR protein (Fig. 3D). 
 
The infectivity of benznidazole-resistant parasites. To investigate the scope for 
drug-resistance in the field to result from loss/inactivation of TcNTR genes, we 
examined the effects of these events on infectivity. First, we generated heterozygous 
parasites to test for haploid insufficiency. One TcNTR allele in the 61S genome was 
disrupted by targeted integration (Fig. S1). The 61S TcNTR+/- epimastigotes grew at 
the same rate in culture as homozygotes, and to the same density. When these 
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heterozygotes were examined for benznidazole-resistance, there had been a 4-fold 
increase (Fig. 4A). These parasites were used to infect rat myoblast L6 cells. No 
differences were observed in the ability of the heterozygotes to develop into infective 
metacyclic trypomastigotes, to invade cells (Fig. 4B), to grow as intracellular 
amastigotes (Fig. 4C) and subsequently to differentiate into bloodstream 
trypomastigotes.  Therefore, drug-resistance that arises through loss of one copy of 
TcNTR is not associated with a reduction in infectivity in vitro.  
 
The infective phenotype of the 61R resistant clones, which contain a single inactive 
copy of TcNTR, was also examined. In culture, epimastigotes differentiated into 
metacyclic trypomastigotes at a level similar to sensitive clones. When culture-
derived trypomastigotes were used to initiate infections, all the resistant clones tested 
(clones 3, 4 and 6) were able to develop through the intracellular cycle as amastigotes 
and differentiate into bloodstream trypomastigotes, which were released following 
host cell lysis. At two levels however, we observed a reduction in virulence. When 
Vero cells were used (Fig. 4D), the number infected by resistant clones was 
significantly less than the level observed with the parental sensitive parasites (Fig. 4E) 
and the average number of amastigotes per infected cell was reduced (Fig. 4F). When 
L6 cells were infected with drug-resistant metacyclics, although released 
trypomastigotes could be observed, their numbers were too few for a quantifiable 
infection assay to be carried out. This compares to an infection rate of ~25% in the 
case of the 61S TcNTR heterozygotes and homozygotes (Fig. 4B). These experiments 
therefore suggest that functional loss of both TcNTR genes, by the mechanisms 
identified here, is associated with a reduction in virulence that would reduce the 
capacity of highly drug-resistant parasites to spread within the population.    
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TcNTR diversity and benznidazole-sensitivity in the field  
To explore possible relationships between natural susceptibility to benznidazole and 
TcNTR, we sequenced the gene from 28 Colombian strains of different biological and 
geographical origins and with a range of benznidazole-sensitivities (IC50 1.5 - 35 μM) 
(Table 1). TcNTR length varied between 939 - 951 nucleotides in these strains, mainly 
due to changes in the copy number of a trinucleotide (ATC)5-9 located between 
residues 210 - 238. This region of the protein is not required for enzyme activity (5). 
Excluding this repeat, we identified 42 polymorphisms, 25 of which were 
nonsynonymous. These amino acid differences were restricted to 7 strains, all but one 
of human origin (Fig. S2, S3). None of the polymorphisms were located in the region 
of TcNTR where we had identified mutations associated with benznidazole-
resistance. Most were located in the amino terminal extension (Fig. S3). The major 
amino acid haplotype group encompassed 21 strains of various biological and 
geographical origins. Importantly, these had a wide range of benznidazole-
sensitivities (IC50 4 - 35 μΜ) (Table 1). This extensive natural variation is therefore 
independent of TcNTR sequence and must be due to other factors. This suggests that 
resistance arising from changes to TcNTR is an acquired trait that requires selective 
pressure.    
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Discussion 
Despite being the front line drug against T. cruzi infections for >40 years, 
benznidazole has drawbacks (24, 25). It can have serious side effects, requires long 
term administration (30-60 days), and its efficacy against chronic stage disease is 
inconsistent. Treatment failures are widely reported, although the extent to which this 
is an acquired trait, or reflects diversity in the level of susceptibility within natural 
parasite populations is unknown (26). As shown here and elsewhere (5, 27, 28), 
laboratory selection of drug-resistant T. cruzi is readily achievable, but in the case of 
benznidazole and nifurtimox, it is only recently that a mechanism has been identified 
(5). Activation of these pro-drugs by the trypanosome type I NTR, an enzyme absent 
from mammals, is central to their mode of action and explains why they are more 
toxic to the parasite than to the host. The 61R benznidazole-resistant T. cruzi clones 
that we investigated were characterised by loss of a 0.85 Mb chromosome band 
containing TcNTR. Genome plasticity is a common phenomenon in trypanosomes 
(29). Confirmation that reduced TcTNR expression caused this resistance was 
provided by reversion of the phenotype following re-introduction of the gene. 
Unexpectedly, we also found that in each of the 61R clones examined, the TcNTR 
gene on the 1.1 Mb chromosome homologue had acquired missense mutation(s) 
which rendered the expressed product enzymatically inactive (Fig. 2,3).  
 
The most parsimonious explanation for our data is that drug pressure led initially to 
selection of benznidazole-resistance due to loss of the TcNTR-containing 0.85 Mb 
chromosome. Continued treatment then resulted in selection, from within this 
population, of distinct lineages in which mutation(s) had inactivated the remaining 
TcNTR gene. The acquisition of two distinct missense mutations in TcNTR of clone 6 
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(nucleotides 374 and 460) implies consecutive events. This two-step process is 
reminiscent of E. coli, where increased nitrofuran-resistance resulted from 
consecutive mutations in the type I NTR genes nfsA and nfsB (23). The mutant 
TcNTR proteins were found to be deficient in FMN-binding. In the NTR group of 
enzymes, location of the flavin-binding is highly conserved within the overall 
structure (22). All of the mutations in TcNTR were restricted to a region (residues 
125-159, Fig. 2), which in the E. coli enzyme, contains residues that interact with the 
isoalloxazine O2, N3, O4 face of FMN (22). The mutation of residue 125 resulted in 
conversion of an evolutionarily conserved proline to a leucine (clones 1, 2, 4, 5 and 
6). At position 154 in clone 6, proline was converted to alanine. Both changes would 
be expected to perturb structure. In clone 3, the mutation associated with disruption of 
FMN-binding involved conversion of phenylalanine 159 to leucine. Phenylalanine is 
present at the corresponding position in E. coli and T. cruzi NTRs (Fig. 2), suggesting 
a functionally conserved role. 
 
The ability of distinct TcNTR-deficient T. cruzi clones to arise independently in a 
single population is strong additional evidence that the drug-activating properties of 
this enzyme (5) are central to the trypanocidal mechanism. The TcNTR single-
knockouts were 4-fold less susceptible to benznidazole (Fig. 4), a level of resistance 
that is significant in the context of this drug, where the therapeutic window is limited 
(3). The virulence properties in vitro were also indistinguishable from TcNTR 
homozygotes. This potential for benznidazole-resistance by a straightforward 
mechanism, coupled with the absence of haploid insufficiency, may explain some of 
the observed treatment failures. The inability of the 61S strain to produce a patent 
infection in mice has restricted us from investigating this further. Complete loss of 
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TcNTR activity in the 61R resistant clones did however have a detrimental effect on 
infectivity in vitro (Fig. 4). This implies that in vivo there will be a limit to the extent 
of benznidazole-resistance achievable by mechanisms involving TcNTR 
(approximately 4-fold), since parasites need to retain a residual level of enzyme 
activity. When we investigated possible relationships between susceptibility to 
benznidazole and TcNTR sequence in a diverse group of parasites (Table 1), we 
found no correlation. These data suggest that natural variation in sensitivity does not 
involve mutations in TcNTR and that resistance by this mechanism may be a trait that 
arises only after selective pressure. Currently, there is no information on the extent to 
which treatment failures reflect natural or acquired resistance.   
 
An observation, which has wider implications for treatment of Chagas disease, is the 
ease with which drug-resistance can arise. In a single experiment, we identified two 
distinct mechanisms, chromosome loss and point mutation, which acted to reduce 
TcNTR activity. In the latter case, three distinct, independently-acquired mutations 
were identified. T. cruzi is extremely diverse, with a genome characterised by 
extensive and highly variable surface antigen gene families (30). This antigenic 
diversity may have arisen in response to selective immune pressure during evolution 
which acted to limit the proof-reading ability of DNA polymerase and/or DNA repair 
mechanisms. As a consequence, the parasite may have acquired an ability to readily 
develop drug-resistance by mutational mechanisms such as those described here. This 
is an important consideration which should inform drug development strategies for 
Chagas disease.  
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Materials and Methods  
Parasites. T. cruzi MRAT/COL/Gal61 (Table 1; 31) were cultivated in supplemented 
RPMI-1640 medium at 28°C (32). Clones were derived by limiting dilution. 
Transformed T. cruzi were maintained at 10 μg ml-1 blasticidin or 50 μg ml-1 G418. 
Amastigotes were grown in African green monkey kidney (Vero) or rat skeletal 
myoblast L6 cells cultured in RPMI-1640/10% FBS at 37°C in 5% CO2. Intact T. 
cruzi chromosomes were extracted using an agarose-embedding technique (29) and 
fractionated by contour-clamped homogenous field electrophoresis (CHEFE) using a 
BioRad CHEFE Mapper. For analysis of natural benznidazole-sensitivity, TcNTR 
from 28 T. cruzi strains from different regions of Colombia was amplified and 
sequenced.  
 
To generate benznidazole-resistance, epimastigotes were seeded at the IC50 and 
subcultured for several weeks under selective pressure. The drug concentration was 
then doubled and the process repeated. This was continued until a resistant population 
was established (61R) at 50 µM, the reported level of therapeutic resistance (33). 
IC50s were determined by an enzymatic micromethod (34). 2x106 epimastigotes ml-1 
were cultured with different drug concentrations for 72 hours at 28°C in 96-well 
microtitre plates. The plates were then incubated with 10 mg ml-1 3(4,5-
dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide (MTT) for 90 min and MTT 
reduction to formazan crystals measured at 595 nm.  
 
Construction of vectors. For expression of TcNTR, a 708 bp fragment corresponding 
to the catalytic domain of the protein was amplified using DNA from sensitive and 
resistant clones (5). Fragments were digested with BamHI/HindIII, ligated into the 
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vector pTrcHis-C (Invitrogen), and the resulting constructs used to transform E. coli 
BL-21. To express active protein in benznidazole-resistant T. cruzi, the full-length 
TcNTR gene (939 bp) was amplified from 61S DNA and ligated into the 
BamHI/HindIII site of the vector pTEX (21). Parasites were electroporated and 
transformants selected with G418. To generate TcNTR heterozygotes from 61S 
parasites, we used gene disruption with a construct containing a blasticidin-resistance 
cassette (5). All constructs were confirmed by sequencing. 
 
Biochemical analysis.  
E.coli transformed with pTrcHis-TcNTR were treated with IPTG to induce expression 
of recombinant histidine-tagged proteins, which were purified on Ni-NTA columns 
(5, 35). Fractions were analyzed by SDS-PAGE and protein concentrations 
determined by the BCA assay (Pierce). TcNTR activity was measured by following 
the changes in absorbance at 340 nm due to NADH oxidation (5).  
 
The TcNTR flavin co-factor was established by determining the fluorescence 
spectrum in acidic and neutral buffers (36). Purified protein (0.5 mg) was desalted and 
boiled for 5 min. Clarified supernatant (90 µl) was then mixed with 10 µl 50 mM 
NaH2PO4 pH7.6 or 1 M HCl (final pH = 2.2) and the fluorescence profile measured 
with a Gemini Fluorescent Plate Reader (Molecular Devices). The mean fluorescence 
values (excitation λ= 450 nm; emission λ=535 nm) was determined and compared to 
FMN and FAD standards. 
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Fig. 1. Properties of T. cruzi clones derived by benznidazole selection. (A) 
Benznidazole concentration that inhibited growth of resistant parasites (61R non-
cloned population and clones 1-6) and parental (61S) cells by 50% (IC50) (Materials 
and Methods). (B) The 61R cells are cross-resistant to the other nitroheterocycles 
nifurtimox and nitrofurazone. (C) T. cruzi chromosomal DNA separated by CHEFE 
and hybridized with a TcNTR gene probe. Left panel, ethidium bromide stained gel; 
right panel, autoradiograph of gel after Southern blotting. Lane 1, parental 61S; lane 
2, 61R clone 3; lane 3, 61R (non-cloned population). (D) Re-introduction of an active 
copy of TcNTR into benznidazole-resistant parasites (61R clone 2) using the pTEX 
vector reverses the drug-resistance phenotype. Growth inhibition data are the mean of 
3 experiments + standard deviation. An autoradiograph (right) shows BamHI-digested 
DNA from parental 61R clone 2 (lanes 1, 2) and pTEX-TcNTR transformed cells 
(lanes 3, 4) hybridized with a TcNTR gene probe. 
 
Fig. 2. Mutations in TcNTR from benznidazole-resistant T. cruzi. The TcNTR 
schematic identifies the amino terminal extension (excluded from recombinant 
proteins) and the location of putative FMN-binding regions inferred by analogy with 
E. coli nfsB (22). Full-length copies of TcNTR from 61R resistant clones were 
amplified and sequenced. Differences in the amino acid sequence compared to the 
parental TcNTR (61S) were restricted to a single region and are highlighted in red. 
Several 61S clones were sequenced, but no differences were identified. The sequence 
in this region of 61S TcNTR (residues 112-162) is identical to that in the genome 
strain CL Brener (accession no. XP_810645). Mutations in the corresponding region 
of E. coli nfsB which confer nitrofurantoin-resistance are indicated by asterisks (23).  
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Fig. 3. Biochemical analysis of TcNTR from benznidazole-sensitive and resistant T. 
cruzi. (A) Purification of recombinant TcNTR. Upper image, wild type (61S) enzyme; 
lower, clone 4. Protein expression was induced by IPTG (Materials and Methods) and 
a clarified fraction (lane 1) was loaded onto a Ni-NTA column and the flowthrough 
collected (lane 2). The column was washed with 50 then 100 mM imidazole (lanes 3 
and 4) and the recombinant protein eluted with 500 mM imidazole, 1% triton X-100 
(lane 5). The 32 kDa TcNTR band is highlighted by an arrow. Recombinant protein 
from each of the resistant clones was purified in a similar manner. (B) TcNTR activity 
was monitored (340 nm) by following oxidation of NADH (100 μΜ) in the presence 
of wild type or mutant (P125L, clone 4) enzyme (0.2 μg) and benznidazole (100 μΜ). 
(C) Activity (v) of the wild type enzyme (nmol NADH min-1 mg-1) was established by 
this assay with a fixed concentration of NADH (100 μM) in the presence of different 
levels of benznidazole (BNZ) (10-100 μM). (D) Florescence (excitation λ=450nm; 
emission λ=535nm) of the TcNTR co-factor (wild type and P125L) and FMN and 
FAD controls under acidic and neutral conditions (Materials and Methods). (E) 
Activity of wild type and mutant TcNTRs.  
 
Fig. 4. Loss of one copy of TcNTR does not reduce infectivity. Targeted disruption of 
TcNTR in 61S epimastigotes was achieved using a construct which confers 
blasticidin-resistance (Fig. S1). (A) TcNTR heterozygotes are benznidazole-resistant. 
61S TcNTR homozygotes (+/+) and heterozygotes (+/-) were tested to establish their 
IC50. Data are the mean of 3 experiments + standard deviation. (B) Heterozygotes are 
not deficient in infectivity. Cell-derived trypomastigotes were added to an L6 cell 
monolayer at a ratio of 1:5 cells:parasites. Infected cells were counted after 72 hours, 
(experiment performed in triplicate). (C) Heterozygotes are not deficient in their 
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ability to replicate in mammalian cells. Infections were carried out and monitored as 
described above. (D) Infection of Vero cells with 61S sensitive and 61R resistant 
parasites, stained with Giemsa. (1) 61S; (2) 61R clone 3; (3) 61R clone 4; (4) 61R 
clone 6. Arrows indicate intracellular amastigotes 48 hours post-infection. (E) 
Benznidazole-resistant clones are deficient in their ability to infect Vero cells. Values 
shown were from 5 experiments (P<0.05). (F) Benznidazole-resistant clones are less 
able to replicate in Vero cells (P<0.05). 
 
 
Table 1. Natural sensitivity to benznidazole is not associated with TcNTR sequence. 
TcNTR genes were amplified from DNA of 28 Colombian T. cruzi strains and 
sequenced.      
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Strain       GenBank              Biological                           Geographical      Phylogentic       IC50 
                accession No             Origin                                     Origin               Group           (μM) 
AC17    JN043349   Rhodnius pallescens       Chocó        I   6.53 + 1.12  
AMP07   JN043351   Panstrongylus geniculatus  Antioquia      I    17.6 + 0.3   
B114    JN043353   Triatoma dimidiata         Córdoba        I    18.7 + 1.4  
B138    JN043352   T. dimidiata               Córdoba        I    17.6 + 0.7  
B51     JN043354   R. pallescens              Córdoba        I    20.6 + 1.1 
CAS18   JN043345   D. marsupialis             Casanare       I    3.90 + 0.78 
CG      JN043336   Homo sapiens               Caquetá       II    4.61 + 0.35 
GAL52   JN043347   Didelphis marsupialis      Sucre          I    9.07 + 2.06  
GAL61   JN043346   Rattus rattus              Sucre          I    5.85 + 1.51 
HA      JN043337   H. sapiens                 Casanare       I    4.66 + 0.61  
LB53    JN043358   T. dimidiata               Sucre          I    17.0 + 0.7  
MG      JN043339   H. sapiens                 Arauca         I    4.90 + 0.33 
MG10    JN043356   T. dimidiata               Magdalena      I    14.9 + 0.89  
OV1     JN043359   P. geniculatus             Sucre          I    17.4 + 0.76  
OV17    JN043355   P. geniculatus             Sucre          I    22.2 + 2.4 
SN3     JN043361   Rhodnius prolixus          La Guajira     I    34.6 + 1.9  
SN5     JN043360   R. prolixus                La Guajira     I    24.2 + 1.3  
SN6     JN043357   R. prolixus                La Guajira     I    16.9 + 0.9 
SP      JN043342   H. sapiens                 Casanare       I    6.41 + 0.75 
SPR     JN043341   H. sapiens                 Casanare      II    5.32 + 1.08  
STP33   JN043350   R. prolixus               Tolima        I    11.3 + 1.0  
AF1     JN043348   P. geniculatus            Antioquia    II    4.69 + 1.87  
JEM     JN043340   H. sapiens                 Putumayo       I    5.19 + 0.65  
DA      JN043344   H. sapiens                 Boyacá         I    32.8 + 3.3  
FCH     JN043334   H. sapiens              N.de Santander   II    1.50 + 0.51  
MR      JN043338   H. sapiens                 Cesar         II    4.71 + 0.29  
W3534   JN043343   H. sapiens                 Sucre          I    14.0 + 1.3  
YLY     JN043335   H. sapiens                 Putumayo     I/II   4.38 + 0.24  
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